GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Incyte Corporation
Stanford University
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
Magenta Therapeutics, Inc.
Baylor College of Medicine
Jonsson Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Stanford University
Masonic Cancer Center, University of Minnesota
University Health Network, Toronto
Ono Pharmaceutical Co. Ltd
Takeda
Rutgers, The State University of New Jersey